Page last updated: 2024-09-20

dibenzylchlorethamine

Description

Dibenzylchlorethamine: An alpha adrenergic antagonist. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5820
CHEMBL ID3305685
SCHEMBL ID479112
MeSH IDM0454899

Synonyms (46)

Synonym
AA-516/31407024
n,n-dibenzyl-n-(2-chloroethyl)amine
dibenzyl-2-chloroethylamine
2-chloroethyldibenzylamine
n,n-dibenzyl-beta-chloroethylamine
dibenzyl chlorethylamine
dibenzyl(2-chloroethyl)amine
skf 199
n-(2-chloroethyl)dibenzylamine
dibenzylchlorethamine
dibenzylamine, n-(2-chloroethyl)-
2-(dibenzylamino)ethyl chloride
hsdb 2086
n,n-dibenzyl-2-chloroethylamine
dibenamine
benzenemethanamine, n-(2-chloroethyl)-n-(phenylmethyl)-
brn 2213696
dibenzylchlorethylamine
PDSP2_001084
PDSP1_001100
n,n-dibenzyl-2-chloroethanamine
bdbm81445
nsc_5820
cas_55-43-6
AKOS005459848
51-50-3
unii-43exu2s56h
43exu2s56h ,
4-12-00-02180 (beilstein handbook reference)
STK526670
BBL028457
1-dibenzylamino-2-chloroethane
dibenzyl-(2-chloro-ethyl)-amine
dibenamine [mi]
n,n-dibenzyl-.beta.-chloroethylamine
n,n-dibenzylaminoethyl chloride
n-(2-chloroethyl)-n-(phenylmethyl)benzenemethanamine
dibenamine [hsdb]
SCHEMBL479112
CHEMBL3305685
n,n-dibenzyl-2-chloroethanamine #
DTXSID20199001
sr-01000883996
SR-01000883996-1
2-chloro-n,n-bis(phenylmethyl)ethanamine
Q27258645

Research

Studies (570)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990556 (97.54)18.7374
1990's12 (2.11)18.2507
2000's2 (0.35)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews7 (1.15%)6.00%
Case Studies2 (0.33%)4.05%
Observational0 (0.00%)0.25%
Other600 (98.52%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research Highlights

Dosage (8)

ArticleYear
Discrimination by SZL49 between contractions evoked by noradrenaline in longitudinal and circular muscle of human vas deferens.
British journal of pharmacology, Volume: 136, Issue: 1
2002
Calculation of agonist efficacy, apparent affinity, and receptor population changes after administration of insurmountable antagonists: comparison of different analytical approaches.
Journal of pharmacological and toxicological methods, Volume: 35, Issue: 4
1996
Irreversible blockade of responses to a partial agonist acting at the histamine H1-receptor.
European journal of pharmacology, Jan-22, Volume: 77, Issue: 2-3
1982
Beta-carbolines selectively antagonize the cholecystokinin action in isolated guinea-pig gallbladder muscle.
Japanese journal of pharmacology, Volume: 42, Issue: 4
1986
Relationship between alpha-adrenoceptor occupancy and contractile response in rat vas deferens. Experimental and theoretical analysis.
European journal of pharmacology, Nov-08, Volume: 156, Issue: 3
1988
Purification of histamine receptor (VI). An improved double labeling method with "double protection".
Japanese journal of pharmacology, Volume: 27, Issue: 6
1977
Selective alpha-adrenoceptor blocking actions of a new derivative of 2-halogenotheylamine: 6-(2-bromoethyl)-10,11-methylenedioxy-5,6,7,8-tetrahydrodibenz[c,e]azocine.
Japanese journal of pharmacology, Volume: 26, Issue: 5
1976
Studies on the mode of antagonism between adrenergic beta-mimetics and beta-blocking agents (III). Functional antagonism between beta-mimetics and spasmogens.
Japanese journal of pharmacology, Volume: 26, Issue: 3
1976
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]